New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 2 publications that cite this research output.

2

The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.

Daidzin enhances memory and the antischizophrenia drug olanzapine's effects, possibly through the 5‐HT2A and D2 receptor interaction pathways

Article in Drug Development Research (September 2024)

The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review

Article in Pharmaceuticals (May 2024)